defens natur healthcar firm offer
page full analyst note
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim feb
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
stand largest pure-play medic devic
maker remain forc reckon med-tech
wide rang chronic diseas expans select
product acut care hospit bolster
posit key partner hospit custom
histor focus innov design
manufactur devic address cardiac care neurolog
spinal condit diabet along firm remain
focus fundament strategi innov often first
market new product invest heavili intern
research develop effort well acquir emerg
technolog howev postreform healthcar world
higher hurdl secur reimburs
next-gener technolog slightli shift
strategi focu partner close hospit client
offer greater breadth product servic help
hospit oper effici partner close
integr hospit oper well
posit take advantag busi opportun
value-bas reimburs environ view particular
pioneer risk-bas contract around
cardiac diabet product think
attract hospit client payer alik
alway appreci divers portfolio
certain wane product line would off-set growth
categori addit devic consum use
surgic suit stabil potenti speed bump
individu product line continu focu
gener nearli billion chines sale fiscal
broad portfolio product fit well
firm earlier purchas kanghui hold provid
firm establish network nativ distributor
reach thousand hospit china
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
one largest medic devic compani develop
manufactur therapeut medic devic chronic diseas portfolio
spinal fixat devic neurovascular product surgic tool
compani market product healthcar institut physician
unit state oversea foreign sale account almost
compani total sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
defens natur healthcar firm offer
concern around global recess due coronaviru
disrupt weigh global market
defens natur healthcar hold rel
basi dont expect signific chang
healthcar moat rate may make downward
adjust valuat healthcar account
near-term challeng expect modest chang
rel recent stock price movement base case
call strong econom rebound follow
recess modest impact
healthcar valuat given defens natur
compani howev coronaviru pandem exert
sustain impact economi significantli higher
number patient unemploy uninsur
underinsur could reduc healthcar demand
greater extent expect govern effort reduc
near-term hit keep harder-hit industri
busi effect treatment emerg
near-term effect coronaviru expect critic
therapi crowd elect procedur new
product non-critical-car product fewer elect
procedur weigh devic maker servic
focus covid-specif case could reduc
profit health insur brand drug firm
alreadi focus specialti drug expect less impact
industri drug administ hospit could
still feel crowd coronaviru patient also
clinic develop timelin probabl face
delay due coronaviru disrupt like slow
new product launch addit coronaviru
impact credit market could weigh heavili
indebt compani hospit firm
compani recent complet major acquisit
outlook coronaviru global
economi well potenti new treatment
coronaviru pleas see
widespread diseas drug pipelin progress
increas fair valu estim per share
increment rais long-term
assumpt earn growth basi point reflect
firm strong new product pipelin continu
incorpor fairli optimist expect innov
structur heart diabet neurovascular unit
well gradual margin expans account effici
program higher-margin new product
project averag annual top-lin growth
indic drug-elut balloon insulin pump
on-going develop atrial fibril market
transcathet valv sale defend price eros
near term estim slightli faster averag
annual revenu growth restor therapi group
fiscal driven adopt new technolog
neuromodul neurovascular return
growth spine busi thank addit
legaci gross margin histor
held firm addit covidien lower
roughli basi point firm made
gradual steadi progress rais gross margin
basi point last four year think
compani eke increment improv
next year ration manufactur
asset project normal gross margin roughli
longer term expect cost synergi
emerg sale administr thank
cross-sel bundl product servic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
save expect next year fair valu
estim would rise per share
hand cardiovascular divis remain
mire low-single-digit growth price pressur
corevalv increas intrepid mitral valv fail
mazor robot abl return spine growth product
pull-through emerg fair valu estim
would fall per share
wide moat root domin presenc
highli engin medic devic treat chronic
diseas includ beyond histor stronghold
heart diseas moat come sever
cardiac area compet roughli three
competitor total across heart-rel portfolio
market pacemak icd coronari stent heart valv
neuromodul gener oper
oligopoli switch cost relat
cardiac rhythm manag devic transcathet
spine area moat strengthen high
switch cost surgeon doctor often reli medic
devic sale rep deep devic knowledg well
experi devic usag wide rang
patient result rep play role highli
special expert advis practition
implant program mainten medtron
devic creat sticki relationship medic
practition dynam tend keep spinal surgeon
loyal product long compani
fall far behind competitor come
final wide moat bolster sever
base averag volatil cash flow divers
product portfolio rel less discretionari therapeut
market rate uncertainti medium
atrial
base case assum see
low-single-digit growth busi penetr
risk-bas tyrx contract program grow
complement
endovascular structur heart surgic technolog
expect spinal devic infus regain
double-digit growth seen howev biggest
wild card quickli introduc
meaning innov support favor
clinic evid magnitud product
pull-through emerg new partnership
outsourc agreement forg
firm new product surpris us upsid
increment product revenu associ servic
agreement exceed expect firm lower
manufactur cost wring administr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
intang includ intellectu properti care
nurtur relationship physician thank
persist abil innov often first
market new product variou therapeut area
expect continu record innov base
extens patent portfolio accord independ
patent board hold strongest
intellectu properti posit base number
technolog strength patent
portfolio allow better weather occasion glitch
develop approv process particular new
devic invest neuromodul diabet
spinal product middl late paid
spade although spine
busi hit slower market growth sinc
firm seen double-digit growth diabet
atrial fibril segment
product line wane new clinic data alter
treatment guidelin firm continu invest
emerg technolog includ renal denerv
transcathet mitral valv drive futur growth
addit covidien deepen competit
advantag covidien medic devic segment enjoy
brand recognit technolog innov substanti
record enhanc
increment research invest past year
result steadi stream product upgrad
new technolog covidien devic subseg
oper oligopolist fashion absenc irrat
price competit evolutionari
rather
revolutionari natur innov tend lead
margin share shift industri strong excess
return covidien current rank near top
product categori compet devic vie
mainli johnson johnson rest field
fragment compani
occupi product nich rather compet broadli
big two
seen new entrant make signific inroad
new competitor sometim pop margin rang
less sophist discount price high-end
technolog advanc rare result
defens practition rare switch
competitor product inertia well
up-front train cost surgeon influenc
procur decis arguabl wane establish
player also administr ear covidien
domin number surgic specialti breadth
portfolio render competitor effort displac
cost individu product basi less meaning
moat remain stabl partli thank stabl
oligopoli compet primarili
abbott purchas st jude medic edward
lifesci cardiac devic johnson
johnson hospital-ori surgic devic tool
competitor may trade market share point
sever year rel short product cycl allow
peer regain share fairli quickli
consist control cardiac rhythm
manag market also domin competitor
structur heart spine neuromodul insulin
pump firm continu innov intern well
purchas new complementari technolog remain
forefront medic devic
wake healthcar reform doctor sign
employe healthcar provid think shift
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
realign doctor financi interest
hospit practic group howev alreadi
maneuv better posit partner
hospit healthcar system doctor see
influenc wane wide-rang product portfolio
particularli suit play role way
competitor introduc servic
wrap around devic
new hospit solut servic taken
big step new role manag catheter
electrophysiolog lab deliv oper
effici think hospit could seek firm
servic turn closer integr
servic hospit oper could also rais
switch cost hospit custom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
histor held roughli share
core heart devic also market leader
spinal product insulin pump neuromodul
chronic pain
pipelin contain treatment atrial
fibril mitral valv diseas
denerv hypertens new therapi
prove effect could domin three
often find novel way appli familiar
technolog like use implant electron
pacemak
incontin chronic pain
address
technolog may face stiffer fight
maintain leadership arena
devic indirectli subject medicar
increas pressur
oover year issu number
voluntari recal product although
fatal associ problem
effort hurt doctor confid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
financi health deterior somewhat
financ signific portion covidien merger
new debt issuanc covidien sharehold own
combin entiti time merger
allow combin entiti invert covidien irish
domicil lower tax rate enhanc abil
access oversea cash end januari
owe billion debt around time
adjust ebitda around time
histor sinc firm paid
billion debt think medtron easili shoulder
current debt load peg debt/adjust ebitda around
time rang gener see medic
technolog beyond debt oblig firm aim
return minimum annual free cash flow
sharehold shoot dividend pay-out
ratio consist engag share repurchas
base averag volatil cash flow divers
product portfolio rel less discretionari therapeut
market rate uncertainti medium
babi boomer hit medicar age could futur
cut medicar reimburs device-rel
procedur would translat financi pressur
hospit custom innov name
game medic devic bar rais
wake healthcar reform success secur price
premium new technolog longer given
depend favor clinic data increas regulatori
attent interest conduct extens clinic
trial aftermarket studi could increas develop
cost product recal liabil
inventori write-down occasion sore spot
industri although depart justic wrap
investig off-label use infus product
without issu charg controversi around
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
investig ad uncertainti contribut declin
infus sale potenti investig product
market remain risk medic devic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ceo/ceo subsidiary/chairman
board/chairman board
repres date owner name posit common share held report holder issuer
omar ishrak left lead
ceo chairman littl direct experi
cardiac market devic industri
consid rise star ge ishrak pioneer behind
ge healthcar success entranc china
market -- led effort expand product portfolio
order compet head head local chines imag
compani mindray gave ge substanti
leg midmarket china consid
make number invest
china india identifi emerg market
strateg sourc growth think ishrak bring valuabl
perspect parti think success
push away -centric past
focus organ close potenti
emerg market led firm invest new area
technolog renal denerv spine robot
importantli drive forc behind
effort posit new product servic help
hospit custom improv outcom lower cost -- key
prioriti shift hospit purchas behavior
wake afford act
ishrak cusp step expect
successor presid geoff martha continu firm
focu innov bring extens healthcar
experi day well time
spent restor therapi group
martha also substanti experi busi
develop lead us believ continu
on-going merger
share
fund
share
fund
new york mellon corp
capit research manag compani
think addit former sell-sid analyst mike
weinstein lead corpor strategi intrigu
move believ weinstein bring deep
well med-tech expertis connect industri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
cfo karen parkhil lack came bank
background expect weinstein sharpen
medtron focu activ help streamlin
portfolio includ potenti sale product
busi influenc clarifi firm approach
capit alloc
decis primarili solid occasion
misstep come acquisit like major
acquisit smaller often privat held firm offer
emerg technolog purchas typic dilut
short term technolog still requir much
develop reach commerci though
difficult assess valu purchas
tend view invest akin intern
invest must make main
concern even though seen
pattern goodwil impair past
hesit poni gener offer certain acquisit
target seem add valu longer term
exampl spent billion purchas
kyphon acquisit turn
disappoint
synergi term sale market physician
relationship abl goos
kyphon product back robust growth howev
think mani acquisit add
valu time includ mazor covidien ardian
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
deliv third-quart fiscal result may
disappoint investor top line howev
firm remain track meet full-year project
like manag kept firm grip
expens weve modestli rais fair valu estim
per share driven primarili slightli higher long-term
earn growth expect firm pipelin support
acceler revenu growth explicit forecast
period despit near-term issu hinder sale growth
third quarter remain confid firm wide
econom moat abil innov
weve seen time time
competitor matter run confluenc factor
may result short-term speed bump case
combin implement new
enterpris softwar system one segment slower
domest growth transcathet aortic valv like
reaction boston scientif re-entri market
lotu devic shift custom
anticip new product
launch previou situat
particularli concern expect one-tim
event time issu iron
importantli pipelin remain robust
better sens new product adopt
next quarter particular interest
uptak percept deep brain stimul parkinson
europ percept offer closed-loop featur allow
devic read individu patient brain signal
input fine-tun devic program
also enthusiast impend launch
medtron new spinal cord stimul devic
incorpor new target pain relief base
upcom american colleg cardiolog
confer horizon especi eager see
data renal denerv technolog among
patient uncontrol hypertens
medic pivot studi
conduct symplic technolog turn
disappoint chill industri enthusiasm
develop variou form technolog cumul
denerv lead sustain improv blood
pressur three year procedur pivot
trial result favor would put
plum posit domin market could eventu
reach billion billion estim
chang fair valu estim
gener consist expect
make subtl adjust project fiscal
leav fair valu estim intact
firm saw constant currenc revenu growth
larg pace med-tech market growth weve
seen wide-moat compani medtron
augment intern innov extern acquisit
technolog deliv stream new product whose
adopt offset slower growth matur product
weve recent seen devic suffer
rel abrupt declin unforeseen complic
come light greater usag intens clinic
studi technolog second quarter medtron
bore brunt practition heed food drug
administr warn significantli higher
mortal rate associ paclitaxel-co balloon
address peripher arteri diseas year year pact
admir balloon sale declin rival becton
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
dickinson alreadi warn may see declin
lutonix drug-coat balloon expect similar
fallout drug-coat coronari stent follow
new clinic data strongli suggest statin drug therapi
effect angioplasti patient narrow
arteri
fortun benefit adopt new
stapl tool neurovascular stent retriev
offset wane product
intrigu rel robust growth seen core
spine busi spine market
mire stagnat howev purchas
mazor robot breath new life spine franchis
anticip acceler growth sustain
midterm surgeon train use
robot
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end april
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end april
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
